Indian Journal of Rheumatology, 2022 Background: Programmed cell death 1(PD-1)/programmed cell death ligand 1 (PD-L1) pathway is an immune checkpoint implicated in immune tolerance and involved in the pathogenesis of several autoimmune diseases.
Eman Eissa +6 more
doaj +2 more sources
Cells, 2022 Current research proves that immune dysregulation is a common feature of coronavirus disease 2019 (COVID-19), and immune exhaustion is associated with increased disease mortality.
Paulina Niedźwiedzka-Rystwej +8 more
doaj +3 more sources
Correlation of E-cadherin, vimentin, CD206, programmed cell death receptor 1, and programmed cell death ligand 1 expressions with clinicopathological factors and prognosis in oral squamous cell carcinoma [PDF]
Journal of International Medical ResearchObjective Oral squamous cell carcinoma is the most common malignant tumor occurring in the head and neck region. Current treatment principles are based on radical surgery, supplemented by radiotherapy and chemotherapy.
Zheng-Yi Lai +5 more
doaj +2 more sources
Regulation of the programmed cell death protein 1/programmed cell death ligand 1 axis in relapsing-remitting multiple sclerosis [PDF]
Brain Communications, 2023 Tsaktanis et al. reveal distinct expression patterns of membrane-bound and soluble programmed cell death ligand 1 in relapsing-remitting multiple sclerosis, correlating with disease severity. These findings demonstrate regulation of programmed cell death
Beyer, Tobias +14 more
core +5 more sources
Inhibitory Immune Checkpoints beyond Programmed Cell Death Ligand 1 in Merkel Cell Carcinoma: Abundant Expression of TIGIT Independent of the Presence of Merkel Cell Polyoma Virus [PDF]
Acta Dermato-VenereologicaMerkel cell carcinoma is a rare, aggressive skin cancer in which Merkel cell polyoma virus (MCPyV) is frequently pathogenically involved. After failure of anti-programmed cell death protein 1/programmed cell death ligand 1 immunotherapy, therapeutic ...
Ferdinand Toberer +8 more
doaj +2 more sources
Immunotherapy With Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors in Patients With Advanced Non–Small Cell Lung Cancers: A Multicenter, Retrospective Analysis [PDF]
MedCommThis multicenter retrospective study analyzed data from 1266 patients with advanced non–small cell lung cancer (NSCLC) across five leading hospitals in China. The aim was to evaluate survival outcomes and safety profiles of programmed cell death 1 (PD‐1)
Jiadi Gan +13 more
doaj +2 more sources
Expression of PD-1 and PD-L1 in Breast Carcinoma: Research Protocol for a Cohort Study [PDF]
Journal of Clinical and Diagnostic Research, 2023 Introduction: Breast cancer is the most common malignant tumour and the leading cause of cancer-related death in women is breast cancer. The Immunohistochemistry (IHC) method utilised antigens and antibodies to interact to identify cellular or tissue
Shreya Ghosh +4 more
doaj +1 more source
PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients [PDF]
Journal of Pathology and Translational Medicine, 2017 Background Programmed death ligand 1 (PD-L1) in tumor cells is known to promote immune escape of cancer by interacting with programmed cell death 1 (PD-1) in tumor infiltrating immune cells.
Jiheun Han, Yongkil Hong, Youn Soo Lee
doaj +1 more source
An update on immunotherapy with PD-1 and PD-L1 blockade [PDF]
Yeungnam University Journal of Medicine, 2021 Cancer is the leading cause of death and is on the rise worldwide. Until 2010, the development of targeted treatment was mainly focused on the growth mechanisms of cancer.
Sung Ae Koh
doaj +1 more source
BMC Pulmonary Medicine, 2021 Background Immune checkpoint inhibitors have potential applications in treating various cancers but are associated with immune-related adverse events, such as inflammation, in a wide range of organs; however, allergic inflammation caused by these agents ...
Masanori Harada +11 more
doaj +1 more source